Sanofi has tapped into the artificial intelligence expertise of Chinese biotech Insilico Medicine with a six-compound drug discovery collaboration that could be worth up to $1.2 billion.
Insilico Medicine has raised $60 million in fourth-round financing that will help to fund the advancement of more drugs towards the clinical testing stage.
